Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.54 |
| ▸ | PDE4A | P27815 | 11/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673206 | 1.00 | PDE4B (0.54) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2966972 | 0.92 | PDE4B (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3550817 | 0.92 | PDE4B (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3554026 | 0.91 | PDE4A (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL4077540 | 0.91 | PDE4B (0.44) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3553860 | 0.88 | PDE4A (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1829130 | 0.88 | PDE4A (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3550320 | 0.88 | PDE4B (0.43) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15252404 | 0.87 | PDE4A (0.46) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3557849 | 0.87 | PDE4A (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2818164-A1 | Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis | CELGENE CORPORATION (US) | 2014-12-31 | — | — | EP | claimed |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| EP-2583098-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2013-04-24 | — | — | EP | claimed |
| EP-2555769-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | Celgene Corporation (US) | 2013-02-13 | — | — | EP | claimed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | claimed |
| US-20120149716-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION | 2012-06-14 | — | — | US | claimed |
| EP-2395995-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION (US) | 2011-12-21 | — | — | EP | claimed |
| US-7842691-B2 | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2010-11-30 | — | — | US | claimed |
| WO-2010093588-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION (US) | 2010-08-19 | — | — | WO | claimed |
| EP-1750697-A4 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORP (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2005043971-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2004080393-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2004-09-09 | — | — | US | claimed |
| WO-2004043378-A2 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004043336-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004041181-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | claimed |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | claimed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | PDE4A, PDE4B, IL4 | PDE4B 2/4885PDE4C 4/4885PDE4A 1/4885 |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | IL2, IL6, IL1B | PDE4B 348/4885PDE4C 352/4885PDE4A 295/4885 |
| US-20120149716-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | PDE4B 1724/4885PDE4C 1641/4885PDE4A 1843/4885 |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | PDE4B 561/4885PDE4C 612/4885PDE4A 498/4885 |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | IL2, IL6, BDNF | PDE4B 1668/4885PDE4C 1599/4885PDE4A 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.